Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting in Chicago from July 28-August 1, 2024. The company will host a booth and deliver a presentation on July 30 at 2:00 PM, focusing on their new Co-Dx™ PCR platform for at-home and point-of-care diagnostics. This platform aims to address the global diagnostics gap, with potential applications including tuberculosis (TB) testing.
Co-Dx recently submitted an FDA 510(k) application for a COVID-19 test using this platform. The company will showcase the Co-Dx PCR Pro™ instrument at Booth 2879 and present a scientific poster on July 31. CEO Dwight Egan and Executive VP Joseph Featherstone will discuss Co-Dx's role in the initiative to end TB by 2030. The new platform and associated tests are currently under FDA review and not yet available for sale.
Co-Diagnostics, Inc. (Nasdaq: CODX) ha annunciato la sua partecipazione alla riunione annuale dell'Associazione per la Diagnostica e la Medicina di Laboratorio (ADLM) che si terrà a Chicago dal 28 luglio al 1 agosto 2024. L'azienda avrà uno stand e presenterà una relazione il 30 luglio alle 14:00, focalizzandosi sulla loro nuova piattaforma Co-Dx™ PCR per diagnosi a casa e presso il punto di cura. Questa piattaforma mira a colmare il divario globale nella diagnosi, con potenziali applicazioni tra cui il test per la tubercolosi (TB).
Co-Dx ha recentemente presentato una domanda 510(k) alla FDA per un test COVID-19 utilizzando questa piattaforma. L'azienda mostrerà lo strumento Co-Dx PCR Pro™ allo stand 2879 e presenterà un poster scientifico il 31 luglio. Il CEO Dwight Egan e il VP esecutivo Joseph Featherstone discuteranno il ruolo di Co-Dx nell'iniziativa per porre fine alla TB entro il 2030. La nuova piattaforma e i test associati sono attualmente in fase di revisione da parte della FDA e non sono ancora disponibili per la vendita.
Co-Diagnostics, Inc. (Nasdaq: CODX) anunció su participación en la reunión anual de la Asociación de Diagnósticos y Medicina de Laboratorio (ADLM) que se llevará a cabo en Chicago del 28 de julio al 1 de agosto de 2024. La empresa tendrá un stand y ofrecerá una presentación el 30 de julio a las 2:00 PM, centrada en su nueva plataforma Co-Dx™ PCR para diagnósticos en casa y en el punto de atención. Esta plataforma tiene como objetivo cerrar la brecha diagnóstica global, con aplicaciones potenciales que incluyen pruebas de tuberculosis (TB).
Co-Dx presentó recientemente una solicitud 510(k) a la FDA para una prueba de COVID-19 utilizando esta plataforma. La empresa mostrará el instrumento Co-Dx PCR Pro™ en el stand 2879 y presentará un póster científico el 31 de julio. El CEO Dwight Egan y el VP ejecutivo Joseph Featherstone discutirán el papel de Co-Dx en la iniciativa para poner fin a la TB para el año 2030. La nueva plataforma y las pruebas asociadas están actualmente en revisión por parte de la FDA y aún no están disponibles para la venta.
코다이아그노스틱스, Inc. (Nasdaq: CODX)는 2024년 7월 28일부터 8월 1일까지 시카고에서 열리는 진단 및 연구소 의학 협회(ADLM) 연례 회의에 참가한다고 발표했습니다. 이 회사는 부스를 운영하고 7월 30일 오후 2시에 가정 및 현장 진단을 위한 새로운 Co-Dx™ PCR 플랫폼에 대한 발표를 진행할 예정입니다. 이 플랫폼은 전 세계 진단 격차를 해소하는 것을 목표로 하며, 감염성 질병인 결핵(TB) 검사와 같은 잠재적인 응용 프로그램을 포함하고 있습니다.
코다이아그노스틱스는 이 플랫폼을 사용하여 COVID-19 검사에 대한 FDA 510(k) 신청서를 최근 제출했습니다. 이 회사는 2879번 부스에서 Co-Dx PCR Pro™ 기기를 선보이고 7월 31일에는 과학 포스터를 발표할 예정입니다. CEO 드와이트 이건(Dwight Egan)과 부사장 조셉 피더스톤(Joseph Featherstone)은 2030년까지 결핵을 종식하기 위한 이니셔티브에서 코다이아그노스틱스의 역할에 대해 논의할 것입니다. 새로운 플랫폼과 관련된 검사들은 현재 FDA 검토 중이며, 아직 판매되지 않습니다.
Co-Diagnostics, Inc. (Nasdaq: CODX) a annoncé sa participation à la réunion annuelle de l'Association pour le Diagnostic et la Médecine de Laboratoire (ADLM) qui se déroulera à Chicago du 28 juillet au 1 août 2024. L'entreprise disposera d'un stand et présentera une conférence le 30 juillet à 14h00, axée sur leur nouvelle plateforme Co-Dx™ PCR pour des diagnostics à domicile et au point de soins. Cette plateforme vise à combler le fossé diagnostic mondial, avec des applications potentielles y compris le dépistage de la tuberculose (TB).
Co-Dx a récemment soumis une demande 510(k) à la FDA pour un test COVID-19 utilisant cette plateforme. L'entreprise présentera l'appareil Co-Dx PCR Pro™ au stand 2879 et montrera un poster scientifique le 31 juillet. Le PDG Dwight Egan et le VP exécutif Joseph Featherstone discuteront du rôle de Co-Dx dans l'initiative visant à mettre fin à la TB d'ici 2030. La nouvelle plateforme et les tests associés sont actuellement en cours d'examen par la FDA et ne sont pas encore disponibles à la vente.
Co-Diagnostics, Inc. (Nasdaq: CODX) gab bekannt, dass es an der Jahresversammlung der Association for Diagnostics & Laboratory Medicine (ADLM) in Chicago vom 28. Juli bis 1. August 2024 teilnehmen wird. Das Unternehmen wird einen Stand haben und am 30. Juli um 14:00 Uhr eine Präsentation halten, die sich auf ihre neue Co-Dx™ PCR-Plattform für Heim- und Point-of-Care-Diagnosen konzentriert. Diese Plattform hat das Ziel, die globale Diagnoselücke zu schließen, mit potenziellen Anwendungen, die Tuberkulose (TB)-Tests umfassen.
Co-Dx hat kürzlich einen FDA 510(k)-Antrag für einen COVID-19-Test mit dieser Plattform eingereicht. Das Unternehmen wird das Co-Dx PCR Pro™-Gerät am Stand 2879 präsentieren und am 31. Juli ein wissenschaftliches Poster vorstellen. CEO Dwight Egan und Executive VP Joseph Featherstone werden über die Rolle von Co-Dx in der Initiative zur Beendigung von TB bis 2030 sprechen. Die neue Plattform und die damit verbundenen Tests befinden sich derzeit in der Überprüfung durch die FDA und sind noch nicht zum Verkauf verfügbar.
- None.
- None.
Co-Dx will also be holding a special company presentation to discuss the role of its new at-home and point-of-care Co-Dx™ PCR platform* in closing the global diagnostics gap for an array of potential indications, including tuberculosis (TB). The platform's first FDA 510(k) application, for a COVID-19 test, was submitted in mid-June. Other tests in the pipeline are expected to meet the diverse needs of a global market.
The presentation will take place in Room S102D at 2:00 PM local time on Tuesday, July 30, and will include Co-Dx CEO Dwight Egan and Co-Dx Executive VP of Business Development Joseph Featherstone addressing how the company is taking an advanced position in the worldwide initiative to end TB by 2030.
In addition to the Company's current and planned pipeline of testing products, both for the new platform and for its existing customer base of distributors and clinical laboratories around the world, the Co-Dx booth will showcase the Co-Dx PCR Pro™ instrument, which is currently under FDA review and is not available for sale. The Company will also be presenting a scientific poster, #B-192, at 1:30-2:30 on July 31st.
Attendees interested in learning more are invited to visit the Company at Booth 2879. Information about the ADLM conference may be found here.
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA and are not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the role of our new at-home and point-of-care Co-Dx™ PCR platform in closing the global diagnostics gap for an array of indications. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 14, 2024, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-and-discuss-advancing-pocotc-diagnostics-at-adlm-2024-in-chicago-302208366.html
SOURCE Co-Diagnostics
FAQ
When and where is Co-Diagnostics presenting at the ADLM 2024 conference?
What is the focus of Co-Diagnostics' presentation at ADLM 2024?
Has Co-Diagnostics (CODX) submitted any FDA applications for their new PCR platform?
What products will Co-Diagnostics (CODX) showcase at their ADLM 2024 booth?
When is Co-Diagnostics (CODX) presenting their scientific poster at ADLM 2024?
